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THE SUCCESS of clinical allogeneic organ transplan-tation has led to a shortage of human organ donors. A 
solution to this increasing problem is the use of donor 
organs from outside the human species; Since nonhuman 
primates are not available in sufficient numbers, are too 
expensive to breed and keep, and their use is limited by 
ethical concern, they are very unlikely candidates for 
xenotransplantation. Animals that are readily available in 
sufficient numbers, however, are cattle and pigs. Although 
it is a discordant donor species, the pig has been used as a 
donor species in initial clinical trials of fetal pancreatic islet 
transplantation. 1 Successful clinical xenotransplaritation is 
limited not least by pre-existing natural antibodies (NXA) 
in the serum of the human recipient and by xenophile 
antibodies (XA) , which are induced by the porcine xe-
nograft. The solution to these humoral problems requires a 
threefold experimental approach: (a) a careful antibody 
analysis in the potential xenograft recipient; (b) the elimi-
nation of NXA from the recipient's serum before trans-
plantation; and (c) the down-regulation of xenosensitiza-
tiori-dependent XA. This report continues and extends 
previous attempts from our laboratory to analyze and 
down-regulate these antibodies. 2-4 
It deals with the manipulation of xenophile antibodies in 
the experimental model "rat-antihuman" using 15-deoxy-
spergualin (I5-DOS) and compares the effects with those 
obtained with leflunomide (LF) and cyclophosphamide 
(CY). 15-DOS was chosen for this study because there 
were preliminary reports indicating its efficacy also on 
B-Iymphocyte reactivity5 after our laboratory, among oth-
ers, had shown that 15-DOS was not only well-tolerated, 
but was highly efficient in suppressing cell-mediated allore-
activity in the rat. 6 
MATERIALS AND METHODS 
Animals 
Lewis rats (3-month-old females, MHC:RT-P, specific pathogen-
free; obtained from the Institut fiir Versuchstierzucht, Hannover, 
Germany, and kept under conventional conditions at the Institute 
of Immunology for the duration of the treatment and observation 
period) received 5 x 106 human peripheral blood Iymphocytes 
intraperitoneally (IP) as xenogeneic antigen on day O. IS-DOS was 
applied IP at a dosage of 2.5 mg/kg for 14 days, from day 0 until 
day + 13; CY at a dosage of 20 mg/kg for 6 days, from day 0 until 
day +5; and LF at a dosage of 10 mg/kg for 10 days, from day 0 
until day +9. The dosage of each drug was chosen individually 
depending on its effectiveness at B-lymphocyte suppression7 or 
prolongation of organ allografts in the rat system.6 
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Experimental DeSign 
The experimental design consisted oftwo treatment protocols: (a) 
treatment of nonsensitized LEW rats with IS-DOS to affect NXA; 
and (b) treatment of xeriogeneically sensitized LEW rats (a single 
injection of human PBL on day 0 in combination with either 
IS-DOS, LF, or Cy) to affect sensitization-dependent XA. Drug 
treatment always started on day o. Each protocol included an 
untreated control group of rats. Tail vein blood was collected at 
IO-day intervals for analysis of NXA and XA by standard flow 
cytometry. 
Determination of NXA and XA in Indirect 
Immunofluorescence 
Similar to previous studies,3·4 rat sera were diluted 1 :2, 1 :4, 1 :8, 
etc, to determine IgM and IgG antibody titers in indirect immu-
nofluorescence (FACS) using human PBL as target cells. Second-
ary antibodies were: (a) fluorescein (DTAF)-conjugated goat 
antirat IgG, Fc fragment specific (Dianova, Hamburg, Germany); 
and (b) fluorescein (DTAF)-conjugated F(ab'h fragment goat 
antirat IgM, IL-chain specific (Dianova). The titer was determined 
by the highest serum dilution at which 100% antibody binding was 
observed above background fluorescence. When binding occurred 
beyond titer 1, ie, in the range of 0% to 100%, the antibody 
content was determined indirectly by the percentage of fluores-
cent target PBL. 
RESULTS 
Influence of 15-DOS on NXA 
To analyze whether 15-DOS is effective in down-regulating 
NXA in nonsensitized LEW rats, the drug was applied 
fr'om day 0 until day + 13 at a dosage of 2.5 mg/kg per day. 
The results of this treatment are shown in Fig 1 for both 
IgG (Fig lA) and IgM (Fig IB) and can be summarized as 
follows: 
1. LEW rats, which were bred and raised under specific 
pathogen-free (SPF) conditions, but were then kept 
under conventional conditions for the duration of the 
treatment and observation period of about 100 days, 
increase their production of NXA-IgG antibodies 
constantly. This can be seen from the increasing 
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Fig 1. Effects of 15-deoxyspergualin (15-DOS) on the production 
of natural xenophile antibodies (NXA) in nonsensitized, normal 
LEW rats, which were bred and raised under SPF conditions, but 
kept under conventional stabling conditions for the time of treat-
ment and observation. LEW rats received 2.5 mg/kg per day 
15-DOS from day 0 until day + 13 or remained untreated 
(CONTR). NXA in the rat serum were determined by indirect 
immunofluorescence (FACS) using human PBL as target cells in a 
binding assay. (A) Production of NXA-lgG; (8) production of 
NXA-lgM (n = 5 per group). 
percentage of human PBL target cells reacting with 
the serum NXA. The increase, which is very likely 
due to sudden microbial contamination under the 
new stabling conditions, is limited to the isotype IgG 
and was never seen with NXA-IgM. 
2. IS-DOS, applied for 14 days, significantly inhibits the 
NXA-IgG production increase up to day 90, but it is 
incapable of effectively down-regulating NXA be-
yond background reactivity (untreated control day 
0). 
3. This does not hold for NXA-IgM, which (a) do not 
increase following the change in stabling conditions, 
and (b) remain unaffected by the drug. 
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Fig 2. Effects of 15-deoxyspergualin (15-DOS), leflunomide (LF), 
and cyclophosphamide (CV) on xenosensitization-dependent an-
tibodies (XA) in LEW rats, which were bred, raised; and kept under 
conventional stabling conditions. The rats received a combined 
treatment, consisting of xenoantigen (human PBL) on day 0 and a 
limited course of each drug (15-005, 2.5 mg/kg per day for 14 
days; or LF, 10 mQlkg per day for 10 days; or CV, 20 mglkg per day 
for 6 days; treatment start was always day 0). Another group of 
rats remained untreated (CONTR). (A) Production of XA-lgG; (8) 
production of XA-lgM (n = 5 per group). 
Reduction of NXA and XA by Xenoantigen Plus Drug: A 
Comparative Study USing Different Drugs 
To test the effects of the drugs on antibodies (XA) in 
sensitized animals, a combination treatment, consisting of 
xenoantigen on day 0 and a limited period of drug appli-
cation, was performed using either IS-DOS, LF, or CV. 
The diugs were applied under comparative experimental 
conditions and were tested in indirect immunofluorescence 
(F ACS). Fig 2 shows the results for IgG (Fig 2A) and for 
IgM antibodies (Fig 2B). The main findings are as follows: 
(a) antibody production switches from IgM to IgG isotype 
after xenogeneic sensitization on day 0 (compare titers of 
untreated control animals on day 0 with titers on day 10); 
(b) of the three drugs, CY is the most effective at down-
regUlating XA to or even below background level (IgG and 
IgM titers on day 0); and (c) as to the effects of the 
individual drugs, the strong to moderate effect of LF is 
reversible (see day 30, which is 20 days after termination of 
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LF application). The moderate effect of 15-DOS, however, 
lasts until day 90 (data not shown), whereas the strong 
effect of CY lasts until day 70 (data not shown). 
DISCUSSION 
As documented in Fig 1, 15-DOS has no effect on NXA; 
which were generated in LEW rats under SPF conditions. 
However, 15-DOS develops a significant suppressive ef-
fect on the up-regulation of NXA-IgG antibodies when 
these rats come under normal microbial exposure. The 
pool of natural xenophile antibodies may consist of a 
mixture of antibodies; eg, a product of endogenous im-
mune network regulation ("germ line determined"s) and a 
product of microbial sensitization in postnatal life. 
Our data indicate that a time-limited combined treat-
ment, consisting of a single injectioIi of xenoantigen and a 
time-related drug application, is an effective experimental 
approach to down-regulate the xenograft-dependent hu-
moral immune reactivity, which, in addition to preformed 
natural antibodies (NXA), mediates acute xenograft rejec-
tion. Of the three drugs tested under comparative condi-
tions, the alkylating agent, CY, proved to be the most 
powerful one. This was not unexpected, since CY has 
been known for a long time to be one of the most effective 
drugs with immunosuppressive potential toward B lyin-
phocytes. However, because of its side effects clinicians 
hesitate to use it in patients uriless they have to treat 
severe cases, eg, severe forms of systemic lupus erythem-
atosus.9.1O This disadvantage necessitates a continuous 
search for similarly effective drugs, but with fewer side 
effects. Therefore, 15-DOS and LF were tested. In the 
dosages used, neither of the two substances showed sig-
nificant side effects in rats. Keeping this important point of 
concern in mind, their comparatively moderate immuno-
suppressive effect, which admittedly waS someWhat disap-
pointing, should nevertheless be regarded valuable for the 
manipUlation of xenophile antibodies. To our knowledge 
this is one of the few reports indicating that 15-DOS not 
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only successfully inhibits cell-mediated allograft rejection 
which was also extensively studied in our laboratory,6 bu~ 
that it is also effective in down-regulating B-Iymphocyte 
reactivity.9 This leads to growing interest in xenogeneic 
transplaritation. II •12 CY, 15-DOS, and the isoxazole deriv-
ative, LF, taken together, provide an interesting opportu-
nity to combine immunobiological effectivity of various 
drugs at well-tolerable dosages over limited periods of 
time. 
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